Aptevo reports 81% remission rate for mipletamig in frontline AML; $60M equity line secured

Aptevo Therapeutics Inc.

Mipletamig plus venetoclax/azacitidine: 87% clinical benefit rate, 81% CR/CRi, 65% CR in 31 evaluable patients; no CRS.
RAINIER trial on track for completion and Phase 2 dose selection by year-end 2026.
Q1 2026 cash position $14.5M; raised $0.9M net under SEPAs; secured new $60M SEPA with Yorkville.
Jeff Lamothe appointed CEO; Marvin White transitions to Executive Chair.
Leadership believes the $60M facility extends capital access into 2029 through key catalysts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.